1039 related articles for article (PubMed ID: 28081945)
1. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J
Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945
[TBL] [Abstract][Full Text] [Related]
2. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
[TBL] [Abstract][Full Text] [Related]
3. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema.
Campochiaro PA; Brown DM; Pearson A; Chen S; Boyer D; Ruiz-Moreno J; Garretson B; Gupta A; Hariprasad SM; Bailey C; Reichel E; Soubrane G; Kapik B; Billman K; Kane FE; Green K;
Ophthalmology; 2012 Oct; 119(10):2125-32. PubMed ID: 22727177
[TBL] [Abstract][Full Text] [Related]
4. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema.
Cunha-Vaz J; Ashton P; Iezzi R; Campochiaro P; Dugel PU; Holz FG; Weber M; Danis RP; Kuppermann BD; Bailey C; Billman K; Kapik B; Kane F; Green K;
Ophthalmology; 2014 Oct; 121(10):1892-903. PubMed ID: 24935282
[TBL] [Abstract][Full Text] [Related]
5. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
Holden SE; Kapik B; Beiderbeck AB; Currie CJ
Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759
[No Abstract] [Full Text] [Related]
6. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
Ip MS; Domalpally A; Sun JK; Ehrlich JS
Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy.
Meireles A; Goldsmith C; El-Ghrably I; Erginay A; Habib M; Pessoa B; Coelho J; Patel T; Tadayoni R; Massin P; Atorf J; Augustin AJ
Eye (Lond); 2017 May; 31(5):684-690. PubMed ID: 28085139
[TBL] [Abstract][Full Text] [Related]
8. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial.
Bressler SB; Qin H; Melia M; Bressler NM; Beck RW; Chan CK; Grover S; Miller DG;
JAMA Ophthalmol; 2013 Aug; 131(8):1033-40. PubMed ID: 23807371
[TBL] [Abstract][Full Text] [Related]
9. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience.
El-Ghrably I; Steel DHW; Habib M; Vaideanu-Collins D; Manvikar S; Hillier RJ
Eur J Ophthalmol; 2017 May; 27(3):357-362. PubMed ID: 28165610
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants.
Yang Y; Bailey C; Holz FG; Eter N; Weber M; Baker C; Kiss S; Menchini U; Ruiz Moreno JM; Dugel P; Lotery A;
Eye (Lond); 2015 Sep; 29(9):1173-80. PubMed ID: 26113503
[TBL] [Abstract][Full Text] [Related]
11. The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema.
Vaz-Pereira S; Castro-de-Sousa JP; Martins D; Prates Canelas J; Reis P; Sampaio A; Urbano H; Kaku P; Nascimento J; Marques-Neves C
Ophthalmic Res; 2020; 63(2):114-121. PubMed ID: 31801148
[TBL] [Abstract][Full Text] [Related]
12. Persistent or Recurrent Diabetic Macular Edema After Fluocinolone Acetonide 0.19 mg Implant: Risk Factors and Management.
Cicinelli MV; Rabiolo A; Zollet P; Capone L; Lattanzio R; Bandello F
Am J Ophthalmol; 2020 Jul; 215():14-24. PubMed ID: 32209341
[TBL] [Abstract][Full Text] [Related]
13. CLINICAL EVIDENCE OF THE MULTIFACTORIAL NATURE OF DIABETIC MACULAR EDEMA.
Chakravarthy U; Yang Y; Lotery A; Ghanchi F; Bailey C; Holz FG; Downey L; Weber M; Eter N; Dugel PU
Retina; 2018 Feb; 38(2):343-351. PubMed ID: 28257378
[TBL] [Abstract][Full Text] [Related]
14. Fluocinolone acetonide for the treatment of diabetic macular edema.
Veritti D; Sarao V; Diplotti L; Samassa F; Lanzetta P
Expert Opin Pharmacother; 2017 Oct; 18(14):1507-1516. PubMed ID: 28764565
[TBL] [Abstract][Full Text] [Related]
15. The Clinical Importance of Changes in Diabetic Retinopathy Severity Score.
Ip MS; Zhang J; Ehrlich JS
Ophthalmology; 2017 May; 124(5):596-603. PubMed ID: 28284785
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes.
Currie CJ; Holden SE; Berni E; Owens DR
Curr Med Res Opin; 2017 Oct; 33(sup2):19-31. PubMed ID: 28881143
[TBL] [Abstract][Full Text] [Related]
17. Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies.
Staurenghi G; Feltgen N; Arnold JJ; Katz TA; Metzig C; Lu C; Holz FG;
Br J Ophthalmol; 2018 Jul; 102(7):954-958. PubMed ID: 29051325
[TBL] [Abstract][Full Text] [Related]
18. Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study.
Mansour SE; Kiernan DF; Roth DB; Eichenbaum D; Holekamp NM; Kaba S; Werts E
Br J Ophthalmol; 2021 Mar; 105(3):414-419. PubMed ID: 32461262
[TBL] [Abstract][Full Text] [Related]
19. Quantitative Assessment of Optic Nerve Changes in Patients With Diabetic Macular Edema Treated With Fluocinolone Acetonide Vitreous Implants.
Parrish RK; Traverso CE; Green K; Danis RP;
Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):418-25. PubMed ID: 27183545
[TBL] [Abstract][Full Text] [Related]
20. Real-Time Photographic- and Fluorescein Angiographic-Guided Management of Diabetic Retinopathy: Randomized PRIME Trial Outcomes.
Yu HJ; Ehlers JP; Sevgi DD; Hach J; O'Connell M; Reese JL; Srivastava SK; Wykoff CC
Am J Ophthalmol; 2021 Jun; 226():126-136. PubMed ID: 33529593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]